Scott & Selber’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $4.48M | Buy |
17,124
+48
| +0.3% | +$12.3K | 0.94% | 26 |
|
|
2026
Q2 | $4.3M | Sell |
17,076
-3
| -0% | -$645 | 0.91% | 29 |
|
|
2026
Q1 | $3.71M | Sell |
17,079
-67
| -0.4% | -$14.9K | 0.96% | 30 |
|
|
2025
Q4 | $3.92M | Sell |
17,146
-732
| -4% | -$167K | 0.98% | 27 |
|
|
2025
Q3 | $4.14M | Sell |
17,878
-220
| -1% | -$44.8K | 1.05% | 29 |
|
|
2025
Q2 | $3.36M | Buy |
18,098
+199
| +1% | +$37K | 0.94% | 32 |
|
|
2025
Q1 | $3.75M | Sell |
17,899
-344
| -2% | -$66.9K | 1.2% | 24 |
|
|
2024
Q4 | $3.24M | Sell |
18,243
-46
| -0.3% | -$8.46K | 0.98% | 30 |
|
|
2024
Q3 | $3.61M | Sell |
18,289
-6,063
| -25% | -$1.13M | 1.12% | 25 |
|
|
2024
Q2 | $4.18M | Buy |
24,352
+164
| +0.7% | +$27.2K | 1.33% | 21 |
|
|
2024
Q1 | $4.4M | Sell |
24,188
-175
| -0.7% | -$30.2K | 1.5% | 18 |
|
|
2023
Q4 | $3.78M | Sell |
24,363
-85
| -0.3% | -$12.4K | 1.42% | 19 |
|
|
2023
Q3 | $3.64M | Sell |
24,448
-76
| -0.3% | -$11.2K | 1.51% | 18 |
|
|
2023
Q2 | $3.3M | Sell |
24,524
-74
| -0.3% | -$10.9K | 1.29% | 21 |
|
|
2023
Q1 | $3.92M | Buy |
24,598
+73
| +0.3% | +$11.2K | 1.67% | 15 |
|
|
2022
Q4 | $3.96M | Buy |
24,525
+46
| +0.2% | +$7.05K | 1.78% | 13 |
|
|
2022
Q3 | $3.28M | Buy |
24,479
+115
| +0.5% | +$16.5K | 1.58% | 14 |
|
|
2022
Q2 | $3.73M | Buy |
24,364
+53
| +0.2% | +$8.1K | 1.7% | 13 |
|
|
2022
Q1 | $3.94M | Sell |
24,311
-1,430
| -6% | -$208K | 1.52% | 15 |
|
|
2021
Q4 | $3.48M | Buy |
25,741
+1,170
| +5% | +$138K | 1.24% | 20 |
|
|
2021
Q3 | $2.65M | Buy |
24,571
+5,135
| +26% | +$587K | 1.07% | 24 |
|
|
2021
Q2 | $2.19M | Buy |
19,436
+3,734
| +24% | +$421K | 0.84% | 42 |
|
|
2021
Q1 | $1.7M | Buy |
15,702
+87
| +0.6% | +$9.31K | 0.7% | 55 |
|
|
2020
Q4 | $1.67M | Sell |
15,615
-1,463
| -9% | -$141K | 0.72% | 55 |
|
|
2020
Q3 | $1.5M | Buy |
17,078
+938
| +6% | +$88.3K | 0.67% | 62 |
|
|
2020
Q2 | $1.58M | Buy |
+16,140
| New | +$1.42M | 0.78% | 56 |
|
|
2015
Q1 | – | Sell |
-43,766
| Closed | -$2.86M | – | 66 |
|
|
2014
Q4 | $2.86M | Buy |
43,766
+161
| +0.4% | +$10.2K | 1.92% | 16 |
|
|
2014
Q3 | $2.52M | Sell |
43,605
-1,075
| -2% | -$59.7K | 1.76% | 25 |
|
|
2014
Q2 | $2.52M | Sell |
44,680
-449
| -1% | -$23.6K | 1.68% | 29 |
|
|
2014
Q1 | $2.32M | Buy |
+45,129
| New | +$2.28M | 1.63% | 38 |
|
Other funds holding ABBV
Scott & Selber's ABBV Position: Q3 2026 in Review
Scott & Selber increased its AbbVie (ABBV) stake by 0.28% in Q3 2026, buying an estimated $12.3K and bringing the position to 17,124 shares worth $4.48M. The position accounts for 0.94% of the portfolio, ranked #26.
Scott & Selber first reported a position in ABBV in Q1 2014 and has held it in 30 quarters since. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.
- Scott & Selber held 17,124 shares of AbbVie worth $4.48M as of Q3 2026.
- Scott & Selber bought 48 AbbVie shares in Q3 2026, an estimated $12.3K.
- AbbVie made up 0.94% of Scott & Selber's portfolio in Q3 2026, its #26 holding.
- Scott & Selber first reported a position in AbbVie in Q1 2014 and has held it in 30 quarters since.
- 3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.
Based on Scott & Selber's 13F filing for Q3 2026, filed 21 Oct 2026.